Trial record 1 of 19 for:
paxlovid 10
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (OPTICOV)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05587894 |
|
Recruitment Status :
Recruiting
First Posted : October 20, 2022
Last Update Posted : March 28, 2024
|
Sponsor:
ANRS, Emerging Infectious Diseases
Collaborator:
University Hospital, Geneva
Information provided by (Responsible Party):
Alexandra Calmy, University Hospital, Geneva
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2025 |
| Estimated Study Completion Date : | May 2025 |